Introduction
============

The vascular endothelium is pivotal in all aspects of cardiovascular physiology and pathology. It is well known that patients with diabetes mellitus are subject to an increased risk of developing atherosclerosis, which is the principal cause of heart attack, stroke, and gangrene of the extremities. Diabetes accelerates atherosclerosis ([@b3-vhrm-4-1283]), microangiopathy and abnormalities in small vessel function, complications that significantly contribute to diabetes-induced morbidity ([@b23-vhrm-4-1283]). Aggressive treatment of hyperglycemia has been shown to be associated with a decrease in diabetes-associated complications, but is not sufficient to fully normalize the incidence of cardiovascular disease in patients with diabetes ([@b6-vhrm-4-1283]). This clinical observation suggests that there may be other factors that causally contribute to the development of diabetes complications.

During insulin biosynthesis, the hormone is synthesized as a single polypeptide, proinsulin, which is subsequently proteolytically processed into insulin inside insulin granules. The mature hormone consists of two polypeptides, the so called A- and B-chain, while the connecting peptide is detached and released into the circulation. This proinsulin-connecting peptide, ie, C-peptide, is thus a product of insulin synthesis, and is released together with the mature hormone during hyperglycemia. Thus, when insulin synthesis is impaired, patients will also become C-peptide-deficient. However, recombinant insulin does not contain the C-peptide and recent research indicates that this peptide may play an important physiological role. The current knowledge regarding the effects of C-peptide on proliferation, immune response, and cell growth will be reviewed briefly.

Beneficial effects of C-peptide
===============================

Exogenous C-peptide administration has beneficial effects in many tissues commonly affected by diabetic complications, a finding supported by the fact that pancreas transplantation reduces diabetic lesions after ten years of normoglycemia, when compared to treatment with recombinant insulin ([@b10-vhrm-4-1283]; [@b11-vhrm-4-1283]). Diabetes-induced cardiovascular complications, such as decreased blood flow in the extremities, have been shown to be prevented by C-peptide ([@b24-vhrm-4-1283], [@b26-vhrm-4-1283]; [@b13-vhrm-4-1283]; [@b15-vhrm-4-1283]). In addition, C-peptide improves diabetes-induced erythrocyte deformability, which in turn likely improves oxygen availability and uptake in affected tissues ([@b24-vhrm-4-1283]; [@b8-vhrm-4-1283]; Kunt et al 2000). Furthermore, C-peptide prevents diabetic neuropathy via improvements of endoneural blood flow and by preventing axonal swelling ([@b25-vhrm-4-1283]; [@b53-vhrm-4-1283]). In the kidneys, C-peptide prevents renal damage by reducing glomerular hyperfiltration, hypertrophy, and proteinuria ([@b12-vhrm-4-1283]; [@b54-vhrm-4-1283]; [@b25-vhrm-4-1283]; [@b47-vhrm-4-1283], [@b48-vhrm-4-1283]; [@b21-vhrm-4-1283]; [@b44-vhrm-4-1283]; [@b56-vhrm-4-1283]). Several studies report a reduction of microvascular complications in patients with type 1, as well as type 2, diabetes with circulating concentrations of C-peptide close to physiological levels ([@b11-vhrm-4-1283]; [@b39-vhrm-4-1283]; [@b55-vhrm-4-1283]; [@b49-vhrm-4-1283]; [@b52-vhrm-4-1283]). Pancreatic transplantation, which restores not only insulin secretion, but also that of C-peptide, is associated with prevention and even reversal of diabetic complications ([@b35-vhrm-4-1283]). Despite this, recent research indicates that C-peptide may not be beneficial under all circumstances.

Type 2 diabetes is a disease associated with endothelial dysfunction and the development of insulin resistance. Type 2 diabetes progresses through two stages. In the first stage, tissue insulin action decreases, resulting in increased insulin and C-peptide production. The second stage is reached when "pancreatic exhaustion" causes insulin and C-peptide production to cease. Thus, during disease progression, patients exhibit high circulating concentrations of C-peptide. Atherosclerosis is an inflammatory process, and in addition to hemodynamic and metabolic factors, inflammation appears to be a potential pathogenic mechanism in the development of the disease ([@b43-vhrm-4-1283]). Although it has not been elucidated whether type 2 diabetics suffer from inflammation to a greater extent than type 1 diabetic patients, plasma levels of interleukin-6 (IL-6) appear to be associated with C-peptide concentrations in type 2 diabetic patients ([@b17-vhrm-4-1283]). Interestingly, C-peptide depositions have been found in arteriosclerotic lesions of patients with diabetes ([@b40-vhrm-4-1283]).

Effects of C-peptide on cell proliferation and apoptosis
========================================================

Atherosclerosis is characterized by features of chronic inflammation and proliferative processes. In the development of atherosclerosis, pathological proliferation and migration of vascular smooth muscle cells are critically involved in the formation of atherosclerotic plaques. C-peptide has been shown to prevent vascular dysfunction in diabetic rats ([@b22-vhrm-4-1283]), and to possess antiproliferative effects on vascular smooth muscle cells ([@b32-vhrm-4-1283]), which indicates that treatment with C-peptide may delay disease progression in atherosclerosis. The administration of C-peptide (1 to 100 nM) appears to suppress hyperglycemia-induced hyperproliferation of aortic smooth muscle cells ([@b32-vhrm-4-1283]). The antiproliferative effects of C-peptide on vascular smooth muscle cells are mediated through the inhibited expression of the platelet-derived growth factor-β (PDGF-β) receptor and increased phosphorylation of mitogen-activated protein kinase (MAPK) ([@b32-vhrm-4-1283]). This stimulating effect on MAPK has been described also for other cell types and experimental settings ([@b30-vhrm-4-1283]; [@b65-vhrm-4-1283], [@b64-vhrm-4-1283]). Paradoxically, in other studies, C-peptide has been reported to act as a mitogen by the induction of vascular smooth muscle cell proliferation ([@b60-vhrm-4-1283]), a finding suggesting proatherogenic activities of the peptide. Whether these effects occur *in vivo* remains to be determined.

Atherosclerotic lesions originate from inflammatory and proliferative responses elicited by injuries to the endothelium and smooth muscle of arterial walls. A large number of growth factors, as well as cytokines, chemokines, and vasoregulators, interact to initiate and propagate the disease. The transcription factor nuclear factor kappa B (NF-κB) is of particular interest and plays a pivotal role in the early stages of disease progression. NF-κB orchestrates transcription of genes encoding various cell-adhesion molecules, as well as inducible nitric oxide synthase (iNOS). NF-κB can be activated by inflammatory and proliferative stimuli ([@b61-vhrm-4-1283]), and activated NF-κB is found in vascular smooth muscle cells, endothelial cells, and macrophages in atherosclerotic lesions of human patients ([@b2-vhrm-4-1283]). It has been postulated that NF-κB promotes chronic inflammation and may accelerate diabetic vascular disease. In this context, it is of importance that NF-κB activity is increased during hyperglycemia ([@b46-vhrm-4-1283]; [@b62-vhrm-4-1283]). The inhibition of protein kinase C (PKC), an upstream regulator of NF-κB activity, has been shown to inhibit hyperglycemia-induced NF-κB activation in vascular smooth muscle cells and aortic endothelial cells ([@b46-vhrm-4-1283]; [@b62-vhrm-4-1283]). In Swiss 3T3 fibroblasts, C-peptide (1 nM) has been shown to stimulate the PKC/NF-κB signaling pathway ([@b31-vhrm-4-1283]).

During disease progression in type II diabetes there is typically an increase in circulating concentrations of C-peptide. This correlation may indicate that C-peptide has negative effects on diabetes-associated complications. Alternatively, it is possible to argue that C-peptide is indeed renoprotective, and that disease progression would be further accelerated in the absence of the peptide. Notably, diabetes-associated complications normally develop slower in patients with type I diabetes, where patients have a relative lack of C-peptide, as compared to patients with type II diabetes, where patients typically have increased circulating C-peptide. However, potential mechanisms for this discrepancy have not been thoroughly investigated. In this context, it is intriguing that serum concentrations of the cytokine tumor necrosis factor-alpha (TNF-α) correlates with plasma C-peptide concentrations ([@b20-vhrm-4-1283]; [@b18-vhrm-4-1283], [@b19-vhrm-4-1283]). TNF-α has been implicated as a causative key mediator of insulin resistance through direct interference with insulin signal transduction, TNF-α is an activator of NF-κB ([@b62-vhrm-4-1283]) and has been implicated in the pathogenesis of diabetic nephropathy ([@b41-vhrm-4-1283]). During the development of diabetic nephropathy, TNF-α has been shown to be expressed in renal glomeruli and proximal renal tubules ([@b42-vhrm-4-1283], [@b57-vhrm-4-1283]; [@b9-vhrm-4-1283]). Furthermore, disease progression is associated with increased serum concentrations of TNF-α and shows a positive correlation with urinary protein excretion ([@b16-vhrm-4-1283]; [@b27-vhrm-4-1283]). Additional studies have demonstrated that the administration of TNF-α impairs renal function ([@b51-vhrm-4-1283]), and that inhibition of TNF-α decreases urinary albumin excretion in rats with experimental diabetes ([@b41-vhrm-4-1283]). Cumulatively, the evidence suggests a direct role for TNF-α in the development of diabetic nephropathy, but the link to C-peptide remains controversial.

PI-3 kinase is necessary for cell proliferation and survival, and is involved in TNF-α signaling. The PI-3 pathway is implicated in the pathogenesis of diabetic endothelial dysfunction and atherosclerosis, and also this pathway has been shown to be increased by C-peptide ([@b3-vhrm-4-1283]; [@b14-vhrm-4-1283]; [@b30-vhrm-4-1283]; [@b36-vhrm-4-1283]; [@b60-vhrm-4-1283]), implicating a synergistic effect of C-peptide and TNF-α in aggravating diabetes-associated complications. On the other hand, administration of C-peptide prevented TNF-α-mediated apoptosis in opossum proximal tubular cells ([@b1-vhrm-4-1283]), suggesting a protective role of C-peptide in the progression of diabetes-related kidney disease. Hence, the interactions between TNF-α and C-peptide occur on multiple levels and outcomes may differ between different organs.

In addition to its causal role in vascular disease, NF-κB is also essential for neuronal development and differentiation ([@b2-vhrm-4-1283]; [@b45-vhrm-4-1283]; [@b7-vhrm-4-1283]). In neurons, it may play a pro- or antiapoptotic role, depending on the cell type and the state of the cell ([@b2-vhrm-4-1283]; [@b45-vhrm-4-1283]; [@b7-vhrm-4-1283]). In the presence of insulin, C-peptide has been shown to exert antiapoptotic effects on neuroblastoma cells, and to increase the production of NF-κB ([@b36-vhrm-4-1283]). C-peptide has been suggested to be beneficial in diabetic neuropathy ([@b53-vhrm-4-1283]) by promoting neuronal development, regeneration and cell survival. C-peptide prevents neuronal apoptosis in type 1 diabetes and *in vitro*, C-peptide induces neurite outgrowth and cell-growth of the neuroblastoma cell line SH-SY5Y ([@b36-vhrm-4-1283]; [@b37-vhrm-4-1283]).

To summarize, accumulating data suggest that C-peptide is involved in regulation of cell proliferation and apoptosis on multiple levels, mainly due to its association with inflammatory mediators, such as NF-κB and TNF-α. C-peptide appears to have predominantly antiproliferative effects in smooth muscle cells and beneficial roles in diabetic neuropathy, while renal effects of C-peptide remain controversial. C-peptide may, on the other hand, play a negative role in endothelial dysfunction due to activation of the PI-3 pathway.

Immunoregulatory effects of C-peptide
=====================================

Nitric oxide synthase (NOS) and nitric oxide (NO) regulation are known to be altered in diabetic and inflammatory states ([@b50-vhrm-4-1283]; [@b34-vhrm-4-1283]; [@b40-vhrm-4-1283]). C-peptide increases eNOS and NO activity ([@b26-vhrm-4-1283]; [@b58-vhrm-4-1283]; [@b59-vhrm-4-1283]; [@b38-vhrm-4-1283]). In smooth muscle cells ([@b5-vhrm-4-1283]) and aortic endothelial cells ([@b63-vhrm-4-1283]; [@b58-vhrm-4-1283]), C-peptide has been shown to increase intracellular Ca^2+^, thereby inducing NO production by endothelial NOS (eNOS) and iNOS, causing an NO-dependent vasodilation. In myocardial ischemia-reperfusion, C-peptide has been shown to exert cardioprotective effects through the release of NO ([@b63-vhrm-4-1283]).

The impaired release of NO from the vascular bed will up-regulate adhesion molecules on endothelial cells, thereby increasing leukocyte-endothelium interactions (known as "rolling" and "sticking") ([@b50-vhrm-4-1283]). Early in the development of atherosclerosis, circulating monocytes adhere and migrate into the subendothelial space ([@b40-vhrm-4-1283]). In isolated ischemic and reperfused rat hearts, C-peptide reduces polymorphonuclear cell adherence to vascular endothelium ([@b63-vhrm-4-1283]), and in an *in vivo* rat model of inflammatory vascular dysfunction, a single bolus injection of C-peptide decreased the expression of endothelial cell adhesion molecules on the rat microvascular endothelium, leading to reduced leukocyte rolling and adhesion as well as transmigration in mesenteric venules ([@b50-vhrm-4-1283]). This attenuation of leukocyte-endothelial interactions is mediated by an increase in eNOS synthesis and subsequent release of NO ([@b50-vhrm-4-1283]). Overall, these reports suggest that administration of C-peptide in physiological doses exerts antiinflammatory, and thus antiatherosclerotic effects.

Paradoxically, C-peptide has also been reported to possess proinflammatory properties. C-peptide improves dermal wound healing associated with an increased number of leukocytes adherent to the endothelium ([@b34-vhrm-4-1283]). C-peptide has been reported to co-localize with macrophages and monocytes in artery specimens from diabetic subjects ([@b40-vhrm-4-1283]), and to co-localize with and act as a chemoattractant for CD4-positive lymphocyte and monocytes in early atherosclerotic lesions ([@b59-vhrm-4-1283]). In Swiss 3T3 fibroblasts, C-peptide (1 nM) has been shown to stimulate the transcription of inflammatory genes, such as cyclooxygenase-2 (COX-2), via the activation of a PKC/NF-κB signaling pathway ([@b31-vhrm-4-1283]). In view of these potential effects of C-peptide, it is important to determine whether the net effect of C-peptide supplementation is beneficial or detrimental for the development of diabetes-associated complications.

In summary, the role of C-peptide in the regulation of inflammation remains controversial, and further studies are needed in order to determine in which contexts treatment with C-peptide would be beneficial from an immunomodulatory point of view.

C-peptide-induced effects on angiogenesis
=========================================

It has been suggested that C-peptide has effects on angiogenesis ([@b5-vhrm-4-1283]). There are indications that diabetes induces the up-regulation of oncofetal fibronectin in the retina ([@b29-vhrm-4-1283]), a substance believed to be involved in angiogenesis and normally not found in mature tissue ([@b4-vhrm-4-1283]; [@b28-vhrm-4-1283]). Increased retinal expression of oncofetal fibronectin in diabetic rats is completely prevented by C-peptide treatment ([@b5-vhrm-4-1283]). This normalization of the diabetes-induced up-regulation of oncofetal fibronectin in diabetic retinas, may suggest an important role of C-peptide for the development of microangiopathy.

Conclusion
==========

Given C-peptide's effects on NF-κB, TNF-α, and PKC, plasma C-peptide concentrations may play a pivotal role in the regulation of endothelial function. Thus, prescribed to the right patients, it is likely that C-peptide substitution would reduce the prevalence of diabetes complications. Accumulated evidence suggest that exogenous C-peptide possesses beneficial effects on diabetic complications in type 1 diabetic patients, and likely also in type 2 diabetic patients with relative C-peptide deficiency. However, it may be that C-peptide does not prevent, but rather contributes to and promotes atherogenesis in patients with excess C-peptide production. It remains to be determined whether these seemingly divergent effects reflect tissue- or state-specific mechanisms.

So far, C-peptide studies have given several opportunities for new drug targets and research directions. Also, C-peptide-induced effects on NO production are not restricted to the diabetic state, but have been reported in models of ischemia-reperfusion as well as during inflammation. Concomitantly, the effectiveness of C-peptide in the prevention and reversal of diabetic complications merits further investigation, particularly in human subjects. Protection from diabetes-induced vascular dysfunction by C-peptide administration has been reported in small-scale clinical trials ([@b25-vhrm-4-1283]; [@b15-vhrm-4-1283]), but long-term, large-scale studies need to be conducted in order to determine safety and health outcomes of long-term administration of C-peptide to patients with diabetes. It is not unlikely that C-peptide substitution in physiological doses would improve endothelial dysfunction, prevent or induce the regression of the atherosclerotic lesions and reduce the risk of diabetes complications.
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